Skip to main content

Degenerative Osteoarthritis

4
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Benzoyl peroxide gelPhase 41 trial
Active Trials
NCT03849885Unknown496Est. Dec 2024
Kolon TissueGene
Kolon TissueGeneMD - Rockville
3 programs
1
2
TG-CPhase 31 trial
TG-CPhase 31 trial
TG-CPhase 21 trial
Active Trials
NCT05276011Not Yet Recruiting255Est. Oct 2026
NCT03203330Active Not Recruiting535Est. Jul 2026
NCT03291470Active Not Recruiting531Est. Mar 2026
MEDIPOST
MEDIPOSTKorea - Gyeonggi
1 program
CARTISTEMPHASE_31 trial
Active Trials
NCT01626677Completed103Est. May 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Colorado TherapeuticsBenzoyl peroxide gel
Kolon TissueGeneTG-C
Kolon TissueGeneTG-C
MEDIPOSTCARTISTEM
Kolon TissueGeneTG-C

Clinical Trials (5)

Total enrollment: 1,920 patients across 5 trials

NCT03849885Colorado TherapeuticsBenzoyl peroxide gel

Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty

Start: Feb 2019Est. completion: Dec 2024496 patients
Phase 4Unknown
NCT03291470Kolon TissueGeneTG-C

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Start: Dec 2021Est. completion: Mar 2026531 patients
Phase 3Active Not Recruiting
NCT03203330Kolon TissueGeneTG-C

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Start: Oct 2018Est. completion: Jul 2026535 patients
Phase 3Active Not Recruiting
NCT01626677MEDIPOSTCARTISTEM

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

Start: Jun 2012Est. completion: May 2015103 patients
Phase 3Completed
NCT05276011Kolon TissueGeneTG-C

A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis

Start: Oct 2025Est. completion: Oct 2026255 patients
Phase 2Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.